Company profile
Arcus Biosciences, Inc.
NYSE: RCUS · Healthcare · Biotechnology
#489 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
47DFH 37DQ 68GM 22SS 71
v0.1 · 65/100 weight · provisional
↑ market scale, filing timeliness · ↓ Piotroski F, 3-yr revenue growth
Methodology →Revenue TTM
$236.0M
Rev growth YoY (TTM)
+67.4%
Net income (FY)
-$353.0M
Employees
601
as of 2026-08-08
Market cap
$3.6B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$33.0M$33.0M2025
Net income-$353.0M-$353.0M2025
Operating income-$386.0M-$386.0M2025
Total assets$1.1B$1.1B2025
Liabilities$750.4M$750.4M2021
Equity$631.0M$631.0M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License And Development Services87%
Development Services7%
R&D Services3%
License3%
By geography
Not disclosed.
The read
What is Arcus Biosciences, Inc.’s revenue?
Arcus Biosciences, Inc. booked $33.0M in FY2025 revenue, contracting 35% year over year — slower than 77% of Healthcare companies we track, at a -1069.7% net margin.
Peers · Healthcare
Precision BioSciences, Inc.46DRapid Micro Biosystems, Inc.46DOrchestra BioMed Holdings, Inc.46DC21 Investments Inc.49DGrown Rogue International Inc.52DStereotaxis, Inc.55CNeighbors
Alameda →Key facts
CEOTerry J. Rosen
SectorHealthcare
IndustryBiotechnology
HeadquartersHayward, CA
ExchangeNYSE: RCUS
Employees601
IPO date2018-03-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.